Molecular mechanisms underlying the effects of statins in the central nervous system - PubMed (original) (raw)

Review

Molecular mechanisms underlying the effects of statins in the central nervous system

Amelia J McFarland et al. Int J Mol Sci. 2014.

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins' effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins' effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins' possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Statins inhibit the conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to

l

-mevalonate, the rate-limiting step of the cholesterol synthesis pathway. Adapted from [10].

References

    1. Parsaik A.K., Singh B., Hassan M.M., Singh K., Mascarenhas S.S., Williams M.D., Lapid M.I., Richardson J.W., West C.P., Rummans T.A. Statins use and risk of depression: A systematic review and meta-analysis. J. Affect. Disord. 2014;160:62–67. doi: 10.1016/j.jad.2013.11.026. - DOI - PubMed
    1. Swiger K.J., Manalac R.J., Blumenthal R.S., Blaha M.J., Martin S.S. Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin. Proc. 2013;88:1213–1221. doi: 10.1016/j.mayocp.2013.07.013. - DOI - PubMed
    1. Ni Chroinin D., Asplund K., Asberg S., Callaly E., Cuadrado-Godia E., Diez-Tejedor E., di Napoli M., Engelter S.T., Furie K.L., Giannopoulos S., et al. Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44:448–456. doi: 10.1161/STROKEAHA.112.668277. - DOI - PubMed
    1. McKinney J.S., Kostis W.J. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149–2156. doi: 10.1161/STROKEAHA.112.655894. - DOI - PubMed
    1. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol. 2005;19:117–125. doi: 10.1111/j.1472-8206.2004.00299.x. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources